Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation + vedolizumab
- Development stage
- Unknown
- Lead developer
- McMaster University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Rectal, Intravenous
01
Overview
Fecal microbiota transplantation + vedolizumab is an investigational combination therapy developed by McMaster University for the treatment of active ulcerative colitis. This dual-action approach combines weekly fecal microbiota transplantation (FMT), administered via enema, with vedolizumab induction therapy. FMT is a biologic therapy that aims to restore gut microbiome diversity and address microbiota dysbiosis by transferring intestinal bacteria from healthy anonymous donors to patients. Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin, inhibiting leukocyte trafficking into the intestinal mucosa. The combination is specifically being studied in patients who have failed prior biologic therapies to determine if addressing both immune trafficking and microbial manipulation simultaneously leads to superior clinical outcomes.
- Other names
- FMT and Vedolizumab CombinationFecal Microbiota Transplantation and VedolizumabFMT and Vedolizumab Combination in UC
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)
Beyond the preview
Go deeper on fecal microbiota transplantation + vedolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation + vedolizumab.